Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000, C546S115000, C546S122000
Reexamination Certificate
active
07977351
ABSTRACT:
The present invention provides a compound represented by the formula:wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification.Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6541504 (2003-04-01), Andrews et al.
patent: 6559173 (2003-05-01), Andrews et al.
patent: 6699863 (2004-03-01), Andrews et al.
patent: 6765012 (2004-07-01), Andrews et al.
patent: 7005444 (2006-02-01), Andrews et al.
patent: 7015220 (2006-03-01), Andrews et al.
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO03-084951 (2003-10-01), None
patent: WO2004-050621 (2004-06-01), None
patent: WO2005-107708 (2005-11-01), None
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL; http://en.wikipedia.orglwikilCancer.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>.
Science (1999), vol. 286, 531-537.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Abstract-Database Registry-XP002451352-Oct. 20, 2004.
Abstract-Database Registry-XP002451353-Sep. 26, 2004.
Kendall & Thomas, 1994, Proc. Nat'l Acad. Sci 90: 10705-09.
Jellinek, et al, Biochemistry 33, 1994: 10450-56.
Takano, et al, 1993, Mol. Bio. Cell 4:358A(2076).
Kinsella, et al, 1992, Exp. Cell Res. 199: 56-62.
Wright, et al, 1992, J. Cellular Phys. 152: 448-57.
Mariani, et al, 1994, Proc. Am. Assoc. Cancer Res. 35: 2268.
Kim, et al, 1993, Nature 362: 841-844.
Plowman et al, 1994, DN&P 7(6): 334-339.
Bolen, 1993, Oncogen 8: 2025-2031.
Boral Sougato
Guo Xialing
Malone Thomas C.
Wang Shimiao
Wurster Julie A.
Allergan Inc.
Allergan, Inc.
Condino Debra D.
German Joel B.
Young Shawquia
LandOfFree
Heteroaryl dihydroindolones as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl dihydroindolones as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl dihydroindolones as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662679